Novartis AG and Novavax, Inc.'s Experimental Bird Flu Vaccines Show Promise In Early Trials

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The first human tests of experimental vaccines against a deadly strain of avian flu, using novel technology that could produce millions of doses very quickly, has produced protective antibodies in the vast majority of recipients. Encouraging results in early-stage trials were announced for separate vaccines from Swiss drugmaker Novartis and Novavax, a biotech company based in Rockville, Maryland.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC